Vertex Pharmaceuticals Chairman Jeffrey Leiden's 2019 pay stays at $19M
Vertex Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: April 28, 2020
Vertex Pharmaceuticals reported fiscal year 2019 executive compensation information on April 28, 2020.
In 2019, seven executives at Vertex Pharmaceuticals received on average a compensation package of $6.7M, a 3% decrease compared to previous year.
Average pay of disclosed executives at Vertex Pharmaceuticals
Jeffrey M. Leiden, Chairman, received $19M in total, which is about the same as previous year. 50% of Leiden's compensation, or $9.3M, was in stock awards. Leiden also received $3.5M in non-equity incentive plan, $4.6M in option awards, $1.3M in salary, as well as $73K in other compensation.
Stuart A. Arbuckle, EVP & Chief Commercial Officer, received a compensation package of $6.9M, which increased by 28% compared to previous year. 47% of the compensation package, or $3.2M, was in stock awards.
Reshma Kewalramani, Chief Executive Officer, earned $6.8M in 2019.
Amit Sachdev, EVP & Chief Patient Officer, received $6.2M in 2019, which increases by 9% compared to 2018.
Charles F. Wagner, Jr, Chief Financial Officer, earned $3.5M in 2019.
Paul M. Silva, SVP & Corporate Controller, received $3.2M in 2019.
Ian F. Smith, Chief Financial Officer, earned $1.5M in 2019, a 69% decrease compared to previous year.
Related executives
Jeffrey Leiden
Vertex Pharmaceuticals
Chairman
Reshma Kewalramani
Vertex Pharmaceuticals
Chief Executive Officer
Charles Wagner
Vertex Pharmaceuticals
Chief Financial Officer
Stuart Arbuckle
Vertex Pharmaceuticals
Chief Operating Officer
Amit Sachdev
Vertex Pharmaceuticals
EVP & Chief Patient Officer
Paul Silva
Vertex Pharmaceuticals
SVP & Corporate Controller
Ian Smith
Vertex Pharmaceuticals
Chief Financial Officer
You may also like
Source: SEC filing on April 28, 2020.